摘要
目的探讨孟鲁司特钠联合布地奈德治疗治疗支气管哮喘的临床疗效。方法研究对象选取呼吸内科2016年3月～2017年3月治疗的支气管哮喘(Ba)患者98例,根据不同治疗方法 ,分为研究组与对照组,对照组仅给予布地奈德进行治疗,研究组在前者基础上,联合孟鲁司特钠实施治疗,观察两组的治疗效果并进行对比。结果 (1)治疗后,研究组的总有效率为100.0%,而对照组为85.7%,差异有统计学意义(P<0.05);(2)研究组的PEF%、FEV1等肺功能指标值显著优于对照组(P<0.05);(3)研究组与对照组的不良反应发生情况,差异无统计学意义(P>0.05)。结论孟鲁司特钠联合与布地奈德治疗Ba疗效佳,能显著改善患者气道受限,提高其生活质量,值得推广。
Objective To investigate the clinical efficacy of montelukast sodium combined with budesonide in the treatment of bronchial asthma.Methods 98 patients with Ba(bronchial asthma)who were treated in the department of respiratory medicine from March 2016 to March 2017 were enrolled in the study.According to different treatment methods,they were divided into study group and reference group.The reference group was only given budesonide for treatment.On the basis of the former,the study group was treated with montelukast sodium.And the therapeutic effects of the two groups were observed and compared.Results(1)After treatment,the total effective rate of the study group was 100.0%,while the total effective rate of the reference group was 85.7%,the difference was statistically significant(P<0.05);(2)The study group's PEF%,FEV1 and other lung function indicators were significantly better than those of the reference group(P<0.05);(3)There was no statistical significance in the adverse reactions betwen the study group and the reference group(P>0.05).Conclusion The montelukast sodium combined with budesonide in the treatment of Ba has good efficacy,which can significantly improve the airway limitation of patients and improve their life quality,and is worth promoting.
作者
刘莹
LIU Ying(Department of Respiratory Medicine,Panzhihua Central Hospital in Sichuan Province,Panzhihua617000,China)
出处
《中国现代医生》
2019年第9期96-97,101,共3页
China Modern Doctor
